Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Consensus Target Price from Analysts

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have earned a consensus recommendation of “Hold” from the five ratings firms that are covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $3.33.

A number of research analysts recently weighed in on the company. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. StockNews.com initiated coverage on shares of Syros Pharmaceuticals in a research note on Wednesday. They issued a “sell” rating on the stock. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th.

Syros Pharmaceuticals Trading Down 10.5 %

Shares of NASDAQ SYRS opened at $0.21 on Thursday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The stock has a market cap of $5.63 million, a price-to-earnings ratio of -0.07 and a beta of 1.31. The business has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $2.42. Syros Pharmaceuticals has a 52 week low of $0.18 and a 52 week high of $7.98.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter in the prior year, the company posted ($1.35) EPS. On average, research analysts predict that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

Insider Transactions at Syros Pharmaceuticals

In related news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the transaction, the director now directly owns 41,070 shares in the company, valued at approximately $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.26% of the stock is owned by insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after buying an additional 17,416 shares in the last quarter. Certuity LLC bought a new position in Syros Pharmaceuticals during the 2nd quarter worth approximately $109,000. Exome Asset Management LLC raised its stake in Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after buying an additional 139,400 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in Syros Pharmaceuticals during the 3rd quarter worth approximately $34,000. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.